Donepezil's Effect on Alzheimer's Disease Outcomes

Evidence for Functional Benefit

• The American College of Physicians suggests that donepezil demonstrates clinically significant improvements on the CIBIC-plus, which assesses overall patient function, including general status, cognition, behavior, and activities of daily living 1, 2
• Donepezil's global function improvements are consistently maintained across multiple trials at both 5 mg and 10 mg daily doses, as recommended by the American Academy of Family Physicians 1, 3

Cognitive and Behavioral Domains

• The American College of Physicians found that donepezil produces consistent improvements in cognition as measured by the ADAS-cog, with benefits apparent from week 3 of treatment 1
• Donepezil shows some positive effects on behavioral symptom improvement, according to the American College of Physicians 1, 2

Magnitude of Benefit

• Approximately 20-35% of treated patients show a seven-point improvement on neuropsychologic tests, equivalent to reversing one year's decline, representing a 5-15% benefit over placebo, as reported by the American Academy of Family Physicians 3

Safety and Tolerability

• The American Academy of Family Physicians notes that donepezil's side effects are predominantly mild, transient gastrointestinal symptoms that are dose-related and reduced when taken with food 3
• No hepatotoxicity occurs with donepezil, unlike tacrine, according to the American Academy of Family Physicians 3

Clinical Caveats

• The American Academy of Family Physicians recommends communicating to patients and families that benefits are modest and represent symptom management, not disease cure or reversal 3